Connect Biopharma Holdings Limited (NASDAQ: CNTB) experienced an 11% surge in its stock price recently. The market responded enthusiastically after the biotechnology company released highly favorable clinical trial data for rademikibart, its targeted anti-interleukin-4-receptor alpha antibody. Furthermore, the company announced a strategic financing agreement to strengthen its balance sheet and fund future clinical developments.

Rapid Lung Function Improvements in Asthma and COPD

The company reported compelling preliminary results from its Phase 1 clinical pharmacology study. Researchers administered a single 300 mg dose of intravenous rademikibart as a straightforward two-minute push. Consequently, patients diagnosed with asthma and chronic obstructive pulmonary disease (COPD) demonstrated rapid lung function enhancements.

The data highlights a swift onset of action. Many trial participants showed forced expiratory volume (FEV1) improvements of 200 mL or greater just 15 minutes after receiving the dose. Moreover, patients sustained these meaningful mean FEV1 improvements--ranging from 200 to 400 mL--straight through Day 29 of the observation period.

Comprehensive Phase 3 Success in Atopic Dermatitis

Beyond respiratory conditions, rademikibart demonstrated strong efficacy in dermatological applications. Connect Biopharma detailed successful outcomes from the 52-week RADIANT-AD Phase 3 study, executed in China by partner Simcere Pharmaceutical.

The trial evaluated patients dealing with moderate-to-severe atopic dermatitis, yielding exceptional long-term efficacy metrics. By Week 52, patients achieved the following milestones:

• 96.6% achieved an EASI-75 response.
• 87.1% reached an IGA score of 0 or 1.
• 85.3% achieved an EASI-90 response.

Additionally, the clinical data confirmed that patients tolerated the drug well. The treatment maintained a rigorous safety profile entirely comparable to the placebo group.

Strategic Private Placement Secures $20.2 Million

To support these ongoing clinical initiatives, Connect Biopharma announced a concurrent private placement. The company plans to issue 6,130,000 ordinary shares priced at $3.25 each. Panacea Venture, the firm’s largest current investor, spearheaded this funding round, signaling strong internal confidence in the pipeline. Ultimately, this transaction will generate roughly $20.2 million in gross proceeds before standard fees and expenses, with an expected closing date near March 31, 2026.

Future Clinical Outlook

Looking ahead, Connect Biopharma expects to reach several more critical milestones. The company plans to publish topline data from its two ongoing Phase 2 Seabreeze STAT studies in mid-2026. These trials will systematically evaluate rademikibart as a targeted treatment for acute exacerbations in both asthma and COPD.

For more investor relations information about Connect Biopharma Holdings please visit www.investors.connectbiopharma.com.

The post Connect Biopharma (NASDAQ: CNTB) Shares Spike Following Positive Rademikibart Trial Data appeared first on PRISM MarketView.

COMTEX_476283485/2927/2026-03-31T03:46:22